3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Recurrence
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Optic Nerve Glioma
2
Oligodendroglioma
2
Neoplasms
2
Myelodysplastic Syndromes
2
Medulloblastoma
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma
2
Leukemia
2
Familial ependymoma
2
Dendritic Cell Sarcoma, Interdigitating
2
Choroid Plexus Neoplasms
2
Cachexia
2
Burkitt Lymphoma
2
Body Weight Changes
2
Astrocytoma
2
Wilms Tumor
1
Vomiting
1
Testicular Neoplasms
1
Spinal Cord Neoplasms
1
Sarcoma, Ewing
1
Sarcoma, Endometrial Stromal
1
Sarcoma
1
Ovarian Germ Cell Cancer
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroblastoma
1
Neoplasms, Neuroepithelial
1
Nausea
1
Interventions
ostarine
3
rimabotulinumtoxinB
1
Standard of Care
1
Olanzapine
1
Exercise
1
Enteral Nutrition
1
Electric Stimulation
1
Eicosapentaenoic Acid
1
Diet Therapy
1
Cyproheptadine
1
Creatine
1
Carnitine
1
Botulinum Toxins, Type A
1
Acetylcysteine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Muscular Atrophy
×
Cyproheptadine
×
Clear all
NCT06175273
2025-09-18
POINT
University of Kentucky
Phase 2/3
Completed
19 enrolled